Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition containing orlistat and GLP-1 receptor agonist, and use thereof

A receptor agonist, GLP-1 technology, applied in the field of medicine, can solve unspecified problems, achieve the effects of inhibiting weight gain, high bioavailability, and inhibiting weight loss

Active Publication Date: 2018-12-18
ZHONGSHAN WANHAN PHARM CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And this patent only discloses the bioavailability of oral nanoparticles when the charged excipient is chitosan, which is only 15.3%
[0009] Chinese patent application CN107708667A (hereinafter referred to as "Reference Document 2") discloses a block copolymer or graft copolymer comprising a) a therapeutically effective amount of liraglutide, b) comprising a hydrophilic portion and a hydrophobic portion , or a mixture thereof, c) at least one hydrophilic lipid molecule, and d) a long-lasting composition of an aqueous carrier, and it is pointed out in its specification that the "graft copolymer" includes 2-methacryloyl Oxyethyl phosphorylcholine (MPCTM) and n-butyl methacrylate (BMA) copolymers (PUREBRIGHT mb-37-50T and PUREBRIGHT mb-37-100T), but the composition described in this patent is in the form of a gel , only for injection administration, and no examples related to MPC / BMA copolymers are given

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing orlistat and GLP-1 receptor agonist, and use thereof
  • Composition containing orlistat and GLP-1 receptor agonist, and use thereof
  • Composition containing orlistat and GLP-1 receptor agonist, and use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0040] 1.1 Preparation of copolymer

[0041] The present invention adopts the synthesis reaction route shown below to prepare the copolymer shown in formula I. For the convenience of description, it is hereinafter referred to as "copolymer 1", and it is numbered according to the x of the R substituents from small to large. Copolymers 1a-1t.

[0042]

[0043] In the above reaction formula, compounds 2a to 2t are cyclopentenyl fatty acids whose structures are shown in the following formula:

[0044]

[0045] Wherein, x is any integer selected from 0-19.

[0046] Compounds 2a~2t exist in nature, or are commercially available, or adopt the method reported by W.M.Stanley et al. (Journal of the American Chemical Society, 1929,51(5):1515~1518) from two carbons less prepared from cyclopentenyl fatty acids.

[0047] Compound 3 and Compound 5 are commonly used chemical raw materials.

[0048] Compound 7 is 2-methacryloyloxyethylphosphorylcholine (MPC), which can be a commercia...

Embodiment 1

[0110] Preparation and structure confirmation of embodiment 1 compound 4k

[0111]

[0112] Preparation: Dissolve 0.252g of compound 2k (1mmol) in 5mL of dichloromethane, stir at -10°C for 5 minutes, then slowly add 0.087mL of oxalyl chloride (1mmol) in 5mL of dichloromethane solution dropwise for 20 minutes After the internal drop is completed, add another drop of N,N-dimethylformamide dropwise, and continue to stir at -10°C for 2 h to obtain solution A; take another 0.063 mL of aminoethanol (1.05 mmol), dissolve it in 5 mL of dichloromethane, and then Add 0.276 mL of triethylamine (2 mmol) dropwise thereto, and stir evenly at -10°C to obtain solution B. Solution A was slowly added dropwise to solution B, and stirring was continued at -10°C for 2h. The reaction solution was washed with 10 mL of 10% sodium carbonate solution, the aqueous layer was extracted with dichloromethane (3×5 mL), and the organic layer was washed with 10 mL of saturated brine. After combining all t...

Embodiment 2

[0116] Preparation and structure confirmation of embodiment 2 compound 6k

[0117]

[0118] Preparation: Take 0.296g of compound 4k (1mmol), 10mL of toluene, 0.125g of p-toluenesulfonic acid and 0.038g of hydroquinone, mix them and put them in a three-necked flask equipped with a water separator, heat and stir until all the solids are dissolved, Further, 0.130 g of methacrylic acid (1.5 mmol) was added to the resulting mixed system. Continue to heat up to the reflux temperature, water and toluene are azeotropic, and are distilled out at the same time. When the amount of water in the water separator is equivalent to the theoretical value (about 0.018g), unreacted methacrylic acid and toluene are removed by distillation under reduced pressure. Cool the crude ester in the flask to room temperature, add an appropriate amount of petroleum ether to dissolve completely, neutralize and wash with lye containing 5% sodium carbonate and 1% sodium hydroxide until slightly alkaline, re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicines, and concretely relates to a composition containing orlistat and a GLP-1 receptor agonist, and a use thereof. The composition containing orlistat and the GLP-1 receptor agonist contains orlistat, and nano-particles comprising the GLP-1 receptor agonist and a copolymer. The composition containing orlistat and the GLP-1 receptor agonist has the advantages of realization of combined oral administration of orlistat and the GLP-1 receptor agonist, high bioavailability and good weight gain increase-inhibiting and weight-reducing effects.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a composition comprising orlistat and a GLP-1 receptor agonist and an application thereof. Background technique [0002] Orlistat (orlistat) is a lipase inhibitor weight loss drug developed by Roche Pharmaceuticals. The trade name is Xenical. It was first launched in Europe and the United States in the late 1990s. Approved by the Food and Drug Administration to switch to an over-the-counter drug. Its chemical name is N-formyl-L-leucine (s)-1-[(2s,3s)-3-hexyl-4oxy-2-epoxypropylmethyl]dodecyl ester, also known as Tetrahydrolipstatin (Tetrahydrolipstatin, THL), is a semi-synthetic lipstatin derivative, and its chemical structure is shown in the following formula: [0003] [0004] Orlistat forms a covalent bond with the serine residue of gastropancreatic lipase, thereby inactivating the enzyme and unable to hydrolyze triglycerides in food into absorbable fatty acid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/51A61K45/06A61K31/365A61K38/22A61K38/26A61P3/04
CPCA61K9/0053A61K9/5138A61K31/365A61K38/22A61K38/26A61K45/06A61P3/04A61K2300/00
Inventor 向飞杜志博彭韪
Owner ZHONGSHAN WANHAN PHARM CO LTD